Recent Topics in Obstetrical Ultrasound in Japan—Fetal Tachyarrhythmia and Bradyarrhythmia

Jun Yoshimatsu

**Abstract**

Fetal arrhythmia is frequently found in daily clinical practice. Extrasystole is the most common type of fetal arrhythmia, which is mostly benign and transient. Meanwhile, bradyarrhythmia and tachyarrhythmia are problematic as they cause fetal heart failure. Fetal tachyarrhythmias include supraventricular tachycardia (SVT), atrial flutter (AFL), and ventricular tachycardia (VT). Supraventricular tachycardia are the most commonly reported type of fetal tachyarrhythmia whose mechanisms are classified into AV re-entrant tachycardia (AVRT), AV nodal re-entrant tachycardia (AVNRT), and intra-atrial re-entrant tachycardia (IART). Fetal therapy is performed in cases where extending the gestation period is required. For the fetal therapy of SVT, the classification by VA intervals is used. In 2019, a Japanese prospective study has proposed a protocol of fetal therapy for supraventricular tachyarrhythmia. The efficacy of fetal therapy was 90% (n = 44/49) overall. In fetal bradyarrhythmias, a ventricular rate of <55 bpm is defined as a risk for hydrops fetalis. A prospective study of hydroxychloroquine is currently being conducted in Japan as its prophylactic efficacy was found. An accurate diagnosis is needed to provide appropriate treatment. The recent advancement of ultrasound equipment has enabled higher-resolution imaging than conventional equipment with high temporal and spatial resolutions. In our research, a template matching technique is employed to track tissue architecture in which the speckle pattern is moved to the most similar orientation. With this technique, we estimated the timings of the P and R waves. The reproducibility of such detection for fetuses is currently insufficient. There is still room to be improved.

**Keywords:** Extrasystole, Fetal arrhythmia, Fetal tachyarrhythmias.

Donald School Journal of Ultrasound in Obstetrics and Gynecology (2021): 10.5005/jp-journals-10009-1712

**Introduction**

A fetal arrhythmia occurs in 1–5% of all fetuses and is frequently found in daily clinical practice.1–4 This disease is classified into three broad categories based on heart rate: bradyarrhythmia, tachyarrhythmia, and extrasystoles. Extrasystole is the most common type of fetal arrhythmia; however, it disappears spontaneously in most cases during the fetal and neonatal periods. Thus, few cases require interventions.5,6 Meanwhile, bradyarrhythmia and tachyarrhythmia are problematic as they cause fetal heart failure. Fetal tachycardia is a condition for which fetal therapy is indicated, and its therapeutic options are divided according to the type of this disease. Given that drug selection is associated with the prognosis of fetal arrhythmia, an accurate diagnosis of this disease is vital.7–10 Currently, fetal tachycardia is diagnosed based on ultrasonography because fetal electrocardiography (fECG) and magnetocardiography (fMCG) are unavailable in many medical facilities. The diagnosis of this condition is not technically difficult; however, while performing ultrasonography, understanding the fetal position and angle of the fetal heart and blood vessels is required to diagnose fetal tachycardia accurately. Also, sweep speed should be appropriately adjusted to diagnose tachycardia. There still is a difficulty requiring experience and moderate level skills.

**Tachyarrhythmia**

Fetal tachyarrhythmias which are rather often encountered in practice include supraventricular tachycardia (SVT), atrial flutter (AFL), ventricular tachycardia (VT). These classifications are based on the difference in electrophysiological mechanisms of each condition.

**Atrial Flutter**

During AFL, the second most common fetal tachyarrhythmia, reentrant excitation occurs in the right atrium when excitation conduction moves around the right atrium instead of the normal electrical conduction. Such electrical impulses cause the atria to beat faster, approximately 300 beats per minute (bpm) or more. However, atrioventricular conduction is at a 2:1 or 3:1 ratio because the conduction ability of the atrioventricular node is limited by the refractory period (Fig. 1).

**Ventricular Tachycardia**

Ventricular tachycardia shows frequent ventricular contraction, independent of atrial contraction (i.e., atrioventricular dissociation) in the absence of reverse conduction to the atrium. As a result, blood flow from the atrium to the ventricles per stroke differs. Reflecting this dissociation, pulsed-wave Doppler shows heterogeneous wave height of a ventricular waveform (Fig. 2). Furthermore, a superior vena cava waveform is also heterogeneous and masked by a ventricular waveform when atrial and ventricular contractions overlap. Pulsed-wave Doppler has a potential utility for prenatal diagnosis of fetal ventricular tachycardia secondary to long QT
Recent Topics of Fetal Tachyarrhythmia and Bradyarrhythmia

Supraventricular Tachycardia

Supraventricular tachycardia are the most commonly reported type of fetal tachyarrhythmia defined by a 1:1 atrioventricular (AV) conduction relation with a heart rate of >180 bpm. Reentry is the most common mechanism of SVT, which are classified into AV nodal re-entrant tachycardia (AVNRT), AV re-entrant tachycardia (AVRT), and intra-atrial re-entrant tachycardia (IART). Fetal SVT easily causes heart failure as well as other fetal tachyarrhythmias. Fetal therapy is performed in cases where extending the gestation period is required to prevent premature birth or heart failure. An accurate diagnosis is needed to provide an appropriate treatment according to the protocol. For the fetal therapy of SVT, the classification by VA intervals is used. It depends on the published literature reporting the difference of response to the antiarrhythmic drugs between long VA and short VA group. The VA time is the interval between ventricular contraction and the next atrial contraction and is used to define the following two types: short and long VA times. The VA time is shorter than the atrioventricular (AV) time, which is the interval between atrial contraction and the next ventricular contraction, is short VA times, and the VA time is longer than the AV time in long VA times. In the presence of a short VA interval, a reentry mechanism with slow anterograde and fast retrograde conduction is the most likely diagnosis while long VA interval represents the inverse manner. The classification by VA intervals is depending on the published literature reporting the difference of response to the antiarrhythmic drugs between long VA and short VA group. In 2019, a Japanese prospective study has proposed a protocol of fetal therapy for supraventricular tachyarrhythmia. A protocol of therapy proposed for fetal tachyarrhythmia (supraventricular tachyarrhythmia) from Japanese group is shown in Figure 4. In the study, the treatment protocol was determined by considering the absence or presence of hydrops fetalis when fetal tachyarrhythmias were classified into SVT with short VA, SVT with long VA or AFL. The efficacy of fetal therapy was 90% (n = 44/49) overall and 75% (n = 3/4) in fetuses with tachyarrhythmias who concomitantly had hydrops fetalis. The onset of a new arrhythmia, fetal death, and reproducibility of arrhythmia after birth were confirmed in mothers and fetuses.

Dissociation between Electrophysiological Phenomena and Actual Heart Movement

M-mode ultrasonography can simultaneously record atrial and ventricular movements. Based on such a feature, atrial and ventricular contractions are regarded as end diastole and systole, respectively. During diastole, the enlargement of the ventricles causes the flow of blood from the atrium to the ventricles, and atrial contraction at the end of the ventricular diastole forces more blood to flow into the ventricles (atrial kick). This hinders the atrioventricular valves from closing and forces them to open again during atrial contraction. The myocardial potential generated by atrial contraction and myocardial potential produced by ventricular contraction corresponds to P and QRS waves, respectively, on ECG. Taken together, M-mode ultrasonography estimates electrophysiological phenomena based on atrial and ventricular movements. Pulsed-wave Doppler shows a reverse wave toward the superior vena cava during atrial contraction, which is regarded as A wave. Furthermore, a ventricular waveform is regarded as a V wave. M-mode ultrasonography estimates electrophysiological phenomena in the heart based on the timing of the actual myocardial movement. Pulsed-wave Doppler estimates electrophysiological phenomena in the heart, based on the changes in blood flow associated with cardiac contraction. However, both methods do not directly evaluate electrophysiological phenomena in the heart. Thus, some dissociations exist between the findings.
obtained using these procedures and those obtained using fMCG. In our institution, the electrical PR interval (ePR) was measured using fMCG (Fig. 5), and the superior vena cava and ascending aorta (SVC–AAo method) and the hepatic vein and descending aorta (HV–DAo method) were simultaneously measured using pulsed-wave Doppler to determine the mechanical PR interval (mPR). The results showed that mPR was longer than ePR (Fig. 6) (unpublished data). That is, a time lag exists between ePR, which represents changes in myocardial potential, and mPR, which represents myocardial tissue movements. Arrhythmia is a disease entity characterized by abnormal electrical conduction. ECG records the myocardial potential. That is, it does not directly record electrical conduction. The electrical impulse is propagated throughout the myocardium, stimulating the atria to contract. Myocardial potential during atrial contraction is observed on ECG. M-mode ultrasonography directly shows the movement of contraction. Pulsed-wave Doppler indicates the blood flow associated with contraction (Fig. 7).

**Development of a New Diagnostic Technology**

B-mode scan ultrasonography is a basic procedure and requires no special skills. Four-chamber view (4CV), the most basic plane to observe the heart, facilitates the visualization of the heart and the acquisition of imaging data. The recent advancement of ultrasound equipment has enabled higher-resolution imaging than conventional equipment with high temporal and spatial resolutions. Furthermore, video clip quality remains high upon increasing the

---

Fig. 4: A protocol of therapy proposed for fetal tachyarrhythmia (supraventricular tachyarrhythmia) from Japanese group. The intrauterine treatment protocol is determined by VA intervals. (Miyoshi et al. Japan Fetal Arrhythmia Group. Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. J Am Coll Cardiol 2019;74:874–885.)

Fig. 5: Fetal magnetic cardiography provides single-averaged fEMG. PR time is accurately measured with this technique.

Fig. 6: The electrical PR interval (ePR) was measured using fMCG, and the mechanical PR is measured by pulsed Doppler. ROI was placed on the superior vena cava and ascending aorta (SVC–AAo method) and the hepatic vein and descending aorta (HV–DAo method). Mechanical PR interval is longer than the electrical PR interval showing the dissociation between the electrical activity and mechanical activity of heart (unpublished data). ePR: electrical PR interval, mPR(SVC-AAo): mechanical PR interval measured by dual gate pulsed Doppler. ROI was placed in SVC and ascending aorta. mPR(HV-DAo): mechanical PR interval measured by dual gate pulsed Doppler. ROI is placed in SVC and ascending aorta.
Bradyarrhythmia

Bradyarrhythmia is defined as a ventricular rate of <100 bpm. Physicians should focus on atrial and ventricular contraction rates while diagnosing bradyarrhythmia. If there is a 1:1 ratio, sinus bradycardia is diagnosed; whereas in other cases, an atrioventricular block is diagnosed. Immune-mediated blocks occur as a result of atrioventricular node deterioration associated with autoantibody-mediated inflammation. RO antigens recognized by anti-SS-A antibodies are a ribonucleoprotein complex that comprises two subunits (52 and 60 kDa). Particularly, anti-RO52 antibodies that recognize the 52-kDa subunit are involved in the onset of atrioventricular blocks. Tissue disorders associated with autoantibodies exert an adverse influence on atrioventricular nodes and the entire heart, resulting in the onset of endocardial fibroelastosis, rupture of the chordae tendineae, dilated cardiomyopathy, and pericardial effusion.

Fetal Therapy for Bradyarrhythmia

A ventricular rate of <55 bpm is defined as a risk for hydrops fetalis. Beta-stimulators are recommended in fetuses with bradyarrhythmia who have a ventricular rate of <55 bpm, or those who have a ventricular rate of 55 bpm or more if they concomitantly have congenital heart disease, abnormal cardiac function, or hydrops fetalis. Steroid treatment has limited efficacy or is ineffective in treating immune-mediated atrioventricular blocks; however, such treatment may be considered in patients with second- or first-degree atrioventricular blocks if they have inflammatory findings. Complete atrioventricular blocks are irreversible; however, a study has reported that a concomitant treatment using steroids and immunoglobulins initiated soon after the onset of a complete atrioventricular block is effective. Early detection of fetal arrhythmia may be associated with a favorable prognosis. However, regular pulse reportedly progresses to complete atrioventricular block within 24 hours in pregnant women who test positive for anti-SS-A antibodies. Steroid use is considered in treating myocarditis during immune-mediated blocks.

Prevention of Atrioventricular Block in Fetuses of Mothers whose Previous Children have Experienced Atrioventricular Blocks

The prevalence of SS-A antibodies in women is 1–2%. An atrioventricular block occurs in 2–4% of fetuses of SS-A antibody-positive mothers; however, this rate increases to 17–21% if their previous children have experienced atrioventricular blocks. Although providing prophylaxis is not recommended in all mothers who test positive for SS-A antibodies, prophylaxis with steroids is considered if their previous children have experienced atrioventricular blocks. A recent study revealed that maternal administration of hydroxychloroquine, a common drug used for treating systemic lupus erythematosus, from the tenth week of gestation has the potential in preventing atrioventricular block in pregnant women with high risk for recurrent atrioventricular block. A prospective study of hydroxychloroquine is currently being conducted in Japan as its prophylactic efficacy was found.

Prediction of Clinical Outcome for Fetal Tachyarrhythmia or Bradyarrhythmia

Our recent study demonstrated that plasma natriuretic peptide levels in umbilical cord blood were correlated with the severity of heart failure in fetuses with congenital heart defects (CHDs) or arrhythmias. Because of the requirement of an invasive procedure, applying an umbilical cord sample is not practical. Following this study, we conducted a single-center, exploratory, cross-sectional study to investigate the possibility of whether maternal serum biomarkers can diagnose fetal heart failure in fetuses with CHDs or
arrhythmias. In this study, 10 fetuses with tachyarrhythmia and 3 with bradyarrhythmia were included. When fetal tachyarrhythmia was sustained for ≥50% of the time on monitoring, fetal therapy using digoxin, sotalol, and flecainide was carried out, and when fetal bradyarrhythmia was complicated with a fetal ventricular rate <55 bpm and myocarditis, beta-sympathomimetics and dexamethasone were used. Maternal serum samples were collected in the third trimester and 1 week after delivery. This study showed that maternal serum concentrations of tumor necrosis factor-α, vascular endothelial growth factor-D, and heparin-binding epidermal growth factor-like growth factor were associated with fetal heart failure in fetal arrhythmia as well as a fetus with CHDs.

**Summary**

It is possible to accurately diagnose fetal arrhythmia including tachy- and bradyarrhythmia by fetal echocardiography followed
Recent Topics of Fetal Tachyarrhythmia and Bradyarrhythmia

by appropriate prenatal management. However, there is still room to be improved especially in severe cases. In this article, recent studies conducted in Japan were reviewed. In addition, the utility of the application of AI for this issue was introduced. Together with genetic surveillance and advanced technology including AI is becoming of importance.

ACKNOWLEDGMENT
The author would like to thank Tomohisa Imamura of Canon Medical Systems for technical assistance with the Artificial Intelligence operation.

REFERENCES

1. Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014;27(21):2183–2242. DOI: 10.1161/01.cir.0000437974.44550.5d.
2. Weber R, Stambach D, Jaeggi E. Diagnosis and management of common fetal arrhythmias. J Saudi Heart Assoc 2011;23(2):61–66. DOI: 10.1016/j.jsaha.2011.01.008.
3. Huhta JC. Fetal congestive heart failure. Semin Fetal Neonatal Med 2005;10(6):542–552. DOI: 10.1016/j.siny.2005.08.005.
4. Inamura N, Horigome H, Takigiki K, et al. Guidelines for fetal echocardiography. Pediatric Cardiology and Cardiac Surgery. 2nd ed., 2021. vol. 37 pp. 2–9.
5. Hajdu J, Pete B, Harmath A, et al. Fetal arrhythmias: a clinical review. Donald School J Ultrasound Obstet Gynecol 2009;3(2):25–37. DOI: 10.5005/jp-journals-10009-1012.
6. Yuan SM. Fetal arrhythmias: surveillance and management. Hellen J Systems for technical assistance with the Artificial Intelligence
The author would like to thank Tomohisa Imamura of Canon Medical

ACKNOWLEDGMENT
The author would like to thank Tomohisa Imamura of Canon Medical Systems for technical assistance with the Artificial Intelligence operation.

REFERENCES

1. Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014;27(21):2183–2242. DOI: 10.1161/01.cir.0000437974.44550.5d.
2. Weber R, Stambach D, Jaeggi E. Diagnosis and management of common fetal arrhythmias. J Saudi Heart Assoc 2011;23(2):61–66. DOI: 10.1016/j.jsaha.2011.01.008.
3. Huhta JC. Fetal congestive heart failure. Semin Fetal Neonatal Med 2005;10(6):542–552. DOI: 10.1016/j.siny.2005.08.005.
4. Inamura N, Horigome H, Takigiki K, et al. Guidelines for fetal echocardiography. Pediatric Cardiology and Cardiac Surgery. 2nd ed., 2021. vol. 37 pp. 2–9.
5. Hajdu J, Pete B, Harmath A, et al. Fetal arrhythmias: a clinical review. Donald School J Ultrasound Obstet Gynecol 2009;3(2):25–37. DOI: 10.5005/jp-journals-10009-1012.
6. Yuan SM. Fetal arrhythmias: surveillance and management. Hellen J Cardiol 2019;60(2):72–81. DOI: 10.1016/j.jhc.2018.12.003.
7. Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation 2011;124(16):1747–1754. DOI: 10.1161/CIRCULATIONAHA.111.026120.
8. Strasburger JF, Wakai RT. Fetal cardiac arrhythmia detection and in utero therapy. Nat Rev Cardiol 2010;7(5):277–290. DOI: 10.1038/nrcardio.2010.32.
9. Kleinman CS, Donnerstein RL, Jaffe CC, et al. Fetal echocardiography: a tool for evaluation of in utero cardiac arrhythmias and monitoring of in utero therapy: analysis of 71 patients. Am J Cardiol 1983;52(2):237–243. DOI: 10.1016/s0002-9149(83)80042-3.
10. Miyoshi T, Maeno Y, Hamasaki T, et al. Antenatal therapy for fetal supraventricular tachyarrhythmias: multicenter trial. J Am Coll Cardiol 2019;74(7):874–885. DOI: 10.1016/j.jacc.2019.06.024.
11. Miyoshi T, Sakaguchi H, Shiraiishi I, et al. Potential utility of pulsed-wave Doppler for prenatal diagnosis of fetal ventricular tachycardia secondary to long QT syndrome. Ultrasound Obstet Gynecol 2018;51(5):696–700. DOI: 10.1002/uog.18819.
12. Kleinman CS, Copel JA, Weinstein EM, et al. In utero diagnosis and treatment of fetal supraventricular tachycardia. Semin Perinatol 1985;9(2):113–129.
13. Bergmans MGM, Jonker GJ, Kock HC. Fetal supraventricular tachycardia: review of the literature. Obstet Gynecol Surv 1985;40(2):61–68. DOI: 10.1097/00006254-198502000-00002.
14. Krapp M, Kohl T, Simpson JM, et al. Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart 2003;89(8):913–917. DOI: 10.1136/heart.89.8.913.
15. Jaeggi E, Fouron JC, Fournier A, et al. Ventricular-atrial time interval measured on M mode echocardiography: a determining element in diagnosis, treatment, and prognosis of fetal supraventricular tachycardia. Heart 1998;79(6):582–587. DOI: 10.1136/hrt.79.6.582.
16. Sridharan S, Sullivan J, Tomek V, et al. Flecainide versus digoxin for fetal supraventricular tachycardia: comparison of two drug treatment protocols. Heart Rhythm 2016;13(9):1913–1919. DOI: 10.1016/j.hrthm.2016.03.023.
17. Malek AS, Elnahrawy A, Anwar H, et al. Automated detection of premature ventricular contraction in ECG signals using enhanced template matching algorithm. Biomed Phys Eng Express 2020;6(1):015024. DOI: 10.1088/2057-1976/ab6995.
18. Chang YL, Hsieh PC, Chang SD, et al. Perinatal outcome of fetus with isolated congenital second degree atrioventricular block without maternal anti-SSA/ Ro-588/La antibodies. Eur J Obstet Gynecol Reprod Biol 2005;122(2):167–171. DOI: 10.1016/j.ejogrb.2005.01.013.
19. Ciardulli A, D’Antonio F, Magro-Malosso ER, et al. Maternal steroid therapy for fetuses with second-degree immune-mediated congenital atrioventricular block: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018;97(7):787–794. DOI: 10.1111/aogs.13338.
20. Izmirly PM, Saxena A, Sahl SK, et al. Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/ Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis 2016;75(6):1161–1165. DOI: 10.1136/annrheumdis-2015-208311.
21. Cuneo BF, Ambrose SE, Tworetzky WT. Detection and successful treatment of emergent anti-SSA-mediated fetal atrioventricular block. Am J Obstet Gynecol 2016;215(4):527–528. DOI: 10.1016/j.ajog.2016.07.002.
22. Yagel S, Silverman NH, Gembruch U. Fetal cardiology: embryology, genetics, physiology, echocardiographic evaluation, diagnosis, and perinatal management of cardiac diseases. 3rd ed., CRC Press; 2019. pp. 515–547.
23. De Carolis S, Garufi C, Garufi E, et al. Autoimmune congenital heart block: a review of biomarkers and management of pregnancy. Front Pediatr 2020;22(8):607515. DOI: 10.3389/fped.2020.607515.
24. Miyoshi T, Umekawa T, Hosoda H, et al. Plasma natriuretic peptide levels in fetuses with congenital heart defect and/or arrhythmia: a single-center prospective study. Ultrasound Obstet Gynecol 2018;52(5):609–616. DOI: 10.1002/uog.18925.
25. Miyoshi T, Hosoda H, Nakai M, et al. Maternal biomarkers for fetal heart failure in fetuses with congenital heart defects or arrhythmias. Am J Obstet Gynecol 2019;220(1):104.e1–104.e15. DOI: 10.1016/j.ajog.2018.09.024.